<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953159</url>
  </required_header>
  <id_info>
    <org_study_id>IRB13-0775</org_study_id>
    <nct_id>NCT01953159</nct_id>
  </id_info>
  <brief_title>Assessment of Paclitaxel-Induced Neuropathy</brief_title>
  <official_title>Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect clinical data, blood samples, and self reported&#xD;
      symptoms from patients that experience unusually severe neuropathy after treatment with&#xD;
      paclitaxel. This data will be used to develop predictive markers for neuropathy. Blood&#xD;
      samples will be used to create induced pluripotent stem (iPS) cells and eventually artificial&#xD;
      nerve cells to be used to study neuropathy in the lab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of polygenic risk score</measure>
    <time_frame>2 years</time_frame>
    <description>Patients will be assessed for neuropathy symptoms and blood samples will be analyzed to detect potential predictive markers</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <description>Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without neuropathy</arm_group_label>
    <description>Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <arm_group_label>Patients without neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Questionnaires</intervention_name>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <arm_group_label>Patients without neuropathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with paclitaxel&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Severe Toxicity Group):&#xD;
&#xD;
          -  Diagnosis of cancer (including, but not limited to, breast and ovarian cancer)&#xD;
&#xD;
          -  Females aged 18 and older&#xD;
&#xD;
          -  History of grade 3 or higher peripheral neurotoxicity, any neuromotor, neurocortical,&#xD;
             or neurocerebellar toxicity, myalgias or arthralgias refractory to non-steroidal&#xD;
             anti-inflammatory drugs and steroids, ong-term persistence (&gt; 6 months) of grade 2 or&#xD;
             higher peripheral neuropathy, or other unusually severe neurotoxicity approved for&#xD;
             inclusion in study by Principal Investigator after completion of paclitaxel&#xD;
             chemotherapy regimen or history of peripheral neuropathy that required treatment with&#xD;
             narcotics or grade 2 or higher peripheral neuropathy after only 1 to 2 doses of&#xD;
             paclitaxel.&#xD;
&#xD;
        Inclusion Criteria (Control Group):&#xD;
&#xD;
          -  History of no neurotoxicity (grade 0) after completion of a standard&#xD;
             paclitaxel-containing chemotherapy regimen&#xD;
&#xD;
          -  Females age 18 and older&#xD;
&#xD;
          -  Matched to a specified subject with neurotoxicity based on age (within 10 years),&#xD;
             tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Treatment with other severely neurotoxic chemotherapy (i.e. cisplatin) prior to or&#xD;
             concomitantly with paclitaxel. Carboplatin therapy is allowed.&#xD;
&#xD;
          -  Presence of peripheral neuropathy prior to paclitaxel therapy&#xD;
&#xD;
          -  Poorly controlled or insulin-dependent diabetes or other condition likely to&#xD;
             predispose to neurotoxicity (alcoholism, Charcot-Marie-Tooth disease)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gini Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

